Avive Solutions Partners with RapidSOS to Create a New Paradigm for Cardiac Arrest Response

Avive Solutions, Inc, is a company bringing to market a revolutionary connected Automated External Defibrillator (AED) coupled with a first of its kind out-of-hospital cardiac arrest (OHCA) response platform.  Today Avive Solutions announced a partnership with RapidSOS.

Together, the solutions are designed to quickly get life-saving AEDs to cardiac arrest patients in their greatest time of need and provide telecommunicators with unprecedented incident data to help them more seamlessly and effectively coordinate life-saving care. Built in partnership with public safety, RapidSOS’s emergency response data platform securely links life-saving data from over 350M connected devices directly to over 5,000 Emergency Communications Centers (ECCs) in North America.

Cardiac arrest is one of the leading causes of death outside the hospital globally. With a mortality rate of ~90% in the United States, OHCA leads to over 350,000 deaths per year. Fortunately, there is a proven therapy for cardiac arrest. While Cardiopulmonary Resuscitation (“CPR”) “buys time,” a person in cardiac arrest ultimately needs to receive a shock delivered from an AED to survive. However, the greatest challenge with cardiac arrest emergencies is time, as every minute a person in cardiac arrest goes without receiving a defibrillation shock reduces their chances of survival by 7-10%. Despite their best efforts, the average response time of Emergency Medical Services (EMS) in the U.S. is 7 minutes, and increasing to more than 14 minutes in more rural locations, making immediate access to an AED and use of the device by everyday people prior to EMS arrival critical for the survival chances of a person in cardiac arrest.

Unfortunately, the status quo today is that an AED is used prior to EMS arrival, only ~2% of the time. This is largely because the locations of AEDs are unknown, and more importantly, because everyday people who may happen to be close to an AED when there is a cardiac arrest emergency nearby, don’t know that device could be used to save a life of someone just minutes away. These examples of critical data gaps pose a great challenge for 911 telecommunicators, who are arguably the most important first responder for cardiac arrest emergencies, as they are tasked with coordinating care with the caller on scene in the earliest, and most crucial, minutes of a cardiac arrest emergency.

Avive Solutions and RapidSOS are committed to developing innovative solutions that aim to take a new approach at improving the status quo of OHCA response. With this partnership, Emergency Communication Centers (ECCs) with access to RapidSOS will be able to dispatch Avive’s intelligent AEDs to the location of a cardiac arrest emergency. Once dispatched, Avive’s AEDs nearby the incident will audibly alert and display a map to navigate willing everyday people to the location of the person in cardiac arrest, creating the potential to greatly increase the likelihood of AEDs being used before EMS arrives on scene.

Beyond dispatching Avive’s AEDs to cardiac arrest emergencies, 911 telecommunicators will also be able to use RapidSOS Portal during the emergency to view incident data from Avive’s AEDs. This incident data includes the location of AEDs as they are en route to the emergency, data from the AED while it’s being used – which is designed to provide 911 dispatchers with insights on if and how they can help a person use the device more quickly and effectively – and much more.

“Every day ~1,000 people of all ages, races, and genders die from cardiac arrest outside of the hospital in the U.S. alone, and tragically survival rates have not appreciably improved over the last two decades,” said Sameer Jafri, President of Avive Solutions, Inc. “We are excited to partner with an innovator like RapidSOS to completely rethink the delivery of life-saving therapy to people suffering cardiac arrest in their greatest time of need.”

According to Michael Martin, CEO of RapidSOS, “We’re united in our commitment to empower safer, stronger communities with intelligent, data-driven emergency response worldwide. Together with Avive, we’re giving telecommunicators the power to activate an added layer of protection during cardiac arrests so that communities can help first responders save more lives.”

While Avive’s AED is in the FDA review cycle, and has not yet been approved for sale in the U.S., cities and counties have already expressed great interest in adopting this solution when it’s available to help improve cardiac arrest response in their community via Avive’s 4-Minute City Program.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”